# Discriminator report

## Scenario echo
The scenario is healthy/baseline human pancreas with no specified age, sex, cell-type subset, or additional notes, so the embedding should cover the broad pancreatic cell landscape: acinar and ductal epithelium, endocrine islet subtypes, vascular and lymphatic endothelium, stromal/stellate and mural compartments, neural/glial cells, and resident immune populations.

## Rating: minor
The blueprint captures the main epithelial, endocrine, stromal, neural, and immune compartments, and most marker choices are biologically plausible. It is not quite complete for an all-cell human pancreas embedding because several expected non-parenchymal populations are collapsed or absent, especially lymphatic endothelium, mural cells, and finer immune subsets.

## Findings

### Minor issues
- **vascular compartment / endothelial_vascular axis** — The blueprint has a single blood endothelial module but no lymphatic endothelial representation. Human pancreas atlases commonly separate vascular endothelial cells from lymphatic endothelial cells, and a broad pancreas embedding should not force lymphatics into a generic PECAM1/VWF/PLVAP vascular score.
  *Fix:* Add a lymphatic endothelial module and axis, ideally under an endothelial structure such as a vascular-vs-lymphatic contrast or a pan-endothelial gated lymphatic axis. Plausible lymphatic markers include `PROX1`, `LYVE1`, `PDPN`, `FLT4`, `CCL21`, `MMRN1`, and `TFF3`, depending on the supporting atlas/resource.

- **stellate_quiescent / stellate_activation_state** — The stromal compartment mixes fibroblast/stellate and mural/pericyte biology: `PDGFRA`, `DCN`, `LUM`, and collagens fit stellate/fibroblast-like cells, while `PDGFRB` and `RGS5` point toward pericytes/mural cells. The activated-stellate axis is also gated by the quiescent module and subtracts the same quiescent module, which may suppress bona fide activated myofibroblastic/stellate cells if they lose quiescent markers.
  *Fix:* Split stromal coverage into at least a fibroblast/stellate module and a mural/pericyte or vascular smooth muscle module. Use markers such as `RGS5`, `CSPG4`, `MCAM`, `NOTCH3`, `PDGFRB`, `ACTA2`, `TAGLN`, and `MYH11` for the mural side as supported. Gate stellate activation by a broader stromal/fibroblast module rather than by a narrowly quiescent marker set.

- **immune compartment axes** — The immune coverage includes macrophage/myeloid, T cell, B cell, and mast cell axes, but it omits expected pancreatic immune subsets such as NK/cytotoxic lymphocytes, plasma cells, and dendritic cells. For a broad healthy human pancreas embedding, collapsing these into T/B/macrophage axes loses biologically meaningful populations.
  *Fix:* Add targeted immune modules where supported by the cited atlases: plasma cells (`MZB1`, `JCHAIN`, `XBP1`, immunoglobulin genes), NK/cytotoxic lymphocytes (`NKG7`, `GNLY`, `PRF1`, `KLRD1`, `GZMB`), and dendritic cells/cDCs (`FCER1A`, `CD1C`, `CLEC10A`, `CLEC9A`, `XCR1`, `LILRA4` as appropriate). These can be plain axes or gated/contrast axes within a broader leukocyte structure if such a module is added.

- **beta_cell and stellate_quiescent marker hygiene** — Several markers are not wrong enough to break the blueprint, but they dilute specificity. `FTL` and `FTH1` in `beta_cell` are generic iron/stress genes rather than beta-cell identity markers, while `FABP4`, `PDGFRB`, and `RGS5` in `stellate_quiescent` blur stellate/fibroblast identity with adipocyte/endothelial or mural programs.
  *Fix:* Replace generic or cross-lineage markers with more specific markers. For beta cells, consider `SLC30A8`, `NKX6-1`, `G6PC2`, `UCN3`, or `HADH` depending on the resource. For stellate/fibroblast, keep matrix/fibroblast markers such as `DCN`, `LUM`, `COL1A1`, `COL1A2`, `COL3A1`, `PDGFRA`, `FAP`, or `CXCL14`, and move mural markers into a separate mural module.

## Out of scope (FYI, not actionable for the Generator)
- I did not verify DOI correctness or journal impact factors; this report only judges biological plausibility and coverage.
- A separate centroacinar/ductal-subtype axis could be useful if strongly supported by the selected atlas resources, but the current ductal core plus ductal mucin state is adequate enough that this is not a required next-round fix.

## Summary for the next round
Focus the refinement on completing non-parenchymal coverage: add lymphatic endothelial and mural/pericyte or vascular smooth muscle structure, expand immune resolution to plasma/NK/DC where supported, and clean up the beta and stromal marker sets so generic stress or mixed-lineage genes do not dilute otherwise canonical modules.
